Structural and Mechanistic Analysis of Two Prolyl Endopeptidases: Role of Interdomain Dynamics in Catalysis and Specificity

Total Page:16

File Type:pdf, Size:1020Kb

Structural and Mechanistic Analysis of Two Prolyl Endopeptidases: Role of Interdomain Dynamics in Catalysis and Specificity Structural and mechanistic analysis of two prolyl endopeptidases: Role of interdomain dynamics in catalysis and specificity Lu Shan†, Irimpan I. Mathews‡, and Chaitan Khosla†§¶ʈ Departments of †Chemical Engineering, ¶Chemistry, and §Biochemistry, Stanford University, Stanford, CA 94305; and ‡Stanford Synchrotron Radiation Laboratory, 2575 Sand Hill Road, Menlo Park, CA 94025 Edited by Christopher T. Walsh, Harvard Medical School, Boston, MA, and approved January 16, 2005 (received for review November 7, 2004) Prolyl endopeptidases (PEPs) are a unique class of serine proteases domain forms a tight barrel-shaped lid over the active site and is with considerable therapeutic potential for the treatment of celiac postulated to regulate substrate size. sprue. The crystal structures of two didomain PEPs have been Mechanisms have been proposed to account for the observed solved in alternative configurations, thereby providing insights bias of PEPs for shorter substrates. It had long been speculated that into the mode of action of these enzymes. The structure of the some conformational change might be involved in substrate binding Sphingomonas capsulata PEP, solved and refined to 1.8-Å resolu- (15). One mechanism suggested that the oscillating ␤-propeller tion, revealed an open configuration of the active site. In contrast, blades act as a ‘‘gating filter’’ during catalysis to let only short the inhibitor-bound PEP from Myxococcus xanthus was crystallized peptide substrates into the active site via the central tunnel of the (1.5-Å resolution) in a closed form. Comparative analysis of the two propeller (12, 13, 16, 17). This proposal was supported by experi- structures highlights a critical role for the domain interface in ments that connected the first and seventh blades of the propeller regulating interdomain dynamics and substrate specificity. Struc- domain with disulfide bonds, which resulted in reduced enzymatic ture-based mutagenesis of the M. xanthus PEP confirms an impor- activity. A more recent study suggests that relative movement of the tant role for several interfacial residues. A salt bridge between two domains might be required to allow substrates into the active Arg-572 and Asp-196͞Glu-197 appears to act as a latch for opening site (18). The nature of the substrate-binding mode is pertinent or closing the didomain enzyme, and Arg-572 and Ile-575 may also from both fundamental mechanistic and practical therapeutic help secure the incoming peptide substrate to the open form of the points of view. Control of chain-length specificity is of particular enzyme. Arg-618 and Asp-145 are responsible for anchoring the importance for the therapeutic use of PEPs in celiac sprue, because invariant proline residue in the active site of this postproline- many of the immunotoxic peptides released by the gastrointestinal cleaving enzyme. A model is proposed for the docking of a metabolism of dietary gluten are relatively long (8, 19). representative substrate PQPQLPYPQPQLP in the active site, where Here, we have solved the x-ray crystal structures of two thera- the N-terminal substrate residues interact extensively with the peutically promising bacterial PEPs from Myxococcus xanthus (MX) catalytic domain, and the C-terminal residues stretch into the and Sphingomonas capsulata (SC) (10). Comparison of the archi- propeller domain. Given the promise of the M. xanthus PEP as an tecture of the two enzymes, one crystallizing in an open (i.e., oral therapeutic enzyme for treating celiac sprue, our results unoccupied) configuration and the other in a closed (i.e., inhibitor- provide a strong foundation for further optimization of the PEP’s bound) configuration, provided direct insight into the mechanism clinically useful features. by which substrate access to the active site is controlled. A docking model of MX PEP with peptide PQPQLPYPQPQLP further celiac sprue ͉ gluten ͉ prolyl oligopeptidase ͉ serine protease revealed an extended binding pocket that could accommodate a larger substrate. Supporting the structural analysis, mutagenesis of rolyl endopeptidases (PEPs), also known as prolyl oligopepti- a salt bridge that hinges the two domains yielded enzymes with Pdases or postproline cleaving enzymes, are a family of serine unaffected catalytic capability but altered chain-length specificity. proteases that cleave after proline residues in peptides. These Alteration of residues responsible for anchoring the invariant proline side chain in the substrate led to greatly reduced catalytic endoproteolytic enzymes are widely distributed in bacteria, fungi, activity, illustrating the delicate interplay between specificity and animals, and plants (1–5). The human PEP is a cytosolic enzyme catalysis in this class of enzymes. involved in physiological processes such as the degradation of certain peptide hormones and neuropeptides. It has been impli- Materials and Methods cated in the regulation of blood pressure and in neurological Expression and Purification of SC and MX PEP. Both PEPs were disorders and is, therefore, an attractive pharmacological target (6, expressed as recombinant proteins with C-terminal His -tags in 7). Recently, PEPs have also been evaluated as oral therapeutic 6 Escherichia coli and purified according the protocols described in agents for celiac sprue because of a unique ability to accelerate the ref. 10. Site-directed mutagenesis was performed by using the PCR breakdown of proline-rich gluten in the gut lumen (8, 9). QuikChange method (Stratagene). From a structural and mechanistic standpoint, PEPs are rela- tively unusual serine proteases. As peptidases, their activity is Crystallization and Diffraction Data Collection. Initial crystallization restricted to substrates that are shorter than 30 amino acid residues, conditions for native SC PEP were determined by using Wizard with the possible exception of the Flavobacterium meningosepticum and Pyrococcus furiosus PEPs, which can break down longer pep- tides (10, 11). PEPs are also significantly larger than typical serine This paper was submitted directly (Track II) to the PNAS office. proteases (75 kDa vs. 30 kDa). The x-ray crystal structure of a Abbreviations: MX, Myxococcus xanthus; PEP, prolyl endopeptidase; pNA, p-nitroanilide; prototypical PEP from porcine muscle was solved by Polgar and SC, Sphingomonas capsulata. coworkers (12–14) and revealed a distinctive two-domain structure, Data deposition: The atomic coordinates have been deposited in the Protein Data Bank, a smaller N-terminal catalytic domain, and an unusual ␤-propeller www.pdb.org (PDB ID codes 2BKL and 1YR2). ʈ domain. The catalytic domain resembles canonical serine proteases To whom correspondence should be addressed. E-mail: [email protected]. BIOCHEMISTRY such as trypsin and chymotrypsin, whereas the unique propeller © 2005 by The National Academy of Sciences of the USA www.pnas.org͞cgi͞doi͞10.1073͞pnas.0408286102 PNAS ͉ March 8, 2005 ͉ vol. 102 ͉ no. 10 ͉ 3599–3604 Downloaded by guest on September 26, 2021 Table 1. Data collection and refinement statistics SC MXϩbocNFP Data collection Space group P21 P21 Unit cell, Å 53.34, 91.22, 79.79 65.69, 114.72, 99.28 ␤ ϭ 91.0° ␤ ϭ 103.6° Wavelength, Å 1.00 1.00 Resolution, Å 50.0–1.80 (1.86–1.80) 50.0–1.50 (1.55–1.50) No. of reflections 353,562 918,495 No. of unique reflections 68,648 225,366 Redundancy 5.2 (2.1) 4.1 (4.0) Completeness 98.9 (92.2) 98.9 (97.7) Rsym,% 7.1 (50.2) 6.8 (47.6) I͞␴ 13.0 (1.7) 12.8 (2.8) Refinement Resolution, Å 30.0–1.80 (1.85–1.80) 30.0–1.50 (1.54–1.50) Reflections (working) 62,633 (4,393) 202,805 (15,555) Reflections (test) 3,538 (237) 11,252 (812) Rwork,* % 16.1 (25.0) 16.0 (22.4) † Rfree, % 18.6 (26.3) 18.2 (25.6) No. of protein atoms 5,252 10,717 No. of ligand atoms 0 67 No. of buffer͞glycerol͞ion atoms 12 41 No. of water atoms 660 1,371 rms deviations Bonds, Å 0.017 0.015 Angles, ° 1.56 1.49 Average B factor, Å2 Protein atoms 16.7 11.0 Ligand atoms N͞A 19.6 Buffer͞glycerol͞ions 47.4 28.5 Solvent atoms 34.7 25.0 Values for the outer shell are given in parentheses. *Rwork ϭ͚hkl ʈFo͉ Ϫ ͉Fcʈ͚͞hkl ͉Fo͉, where Fo and Fc are observed and calculated structure factors, respectively. † For Rfree, the above summation is extended over a subset of reflections (5%) that were excluded from all stages of refinement. I and Wizard II crystal screens (Emerald Biostructures, Bain- Systems) with a crystal-to-detector distance of 190 mm. Both data bridge Island, WA) with 19.4 mg/ml protein in 20 mM Hepes (pH sets were processed and scaled by using HKL2000 (HKL Research, 7.0)͞2mMDTT͞5% glycerol. Crystals were grown at 22°C by Charlottesville, VA) (20, 21). Final data-processing statistics are using the hanging-drop vapor-diffusion technique. The opti- shown in Table 1. mized crystallization conditions involved mixing 1.2 ␮l of protein solution with 1.2 ␮l of reservoir solution containing 23% PEG Structure Determination and Refinement. The structure of the SC 8K and 0.1 M Tris (pH 8.6). Diffraction-quality crystals ap- PEP protein was determined by molecular replacement by using the peared in 2–3 days. Crystals were cryoprotected by 2-min program MOLREP from the CCP4 suite (30). Because the initial stepwise soaks in solutions of the well solution plus 2%, 5%, 8%, attempts with reported structures (closed forms) of the PEPs were 12%, and, finally, 17% glycerol and were then flash-frozen in unsuccessful, individual searches for the catalytic domain and the liquid nitrogen. ␤-barrel domain were performed. This procedure enabled the The complex of MX PEP–Z-Ala-prolinal was prepared by mixing structure solution and revealed the open conformation of the SC the protein sample witha5Mexcess of the ligand. Crystals of the PEP structure. complex were grown at 4°C by using the hanging-drop vapor- The MX PEP structure was determined by molecular replace- diffusion technique.
Recommended publications
  • Chymotrypsin: a Serine Protease Reaction Mechanism Step
    CHEM464/Medh,J.D. Catalytic Strategies Chymotrypsin: A serine protease • Covalent catalysis: temporary covalent modification of reactive • Hydrolyzes peptide bonds on the carboxyl side of group on enzyme active site Tyr, Phe, Trp, Met, Leu • Acid-Base catalysis: A molecule other than water is proton • Since peptide bond is highly unreactive, a strong donor or acceptor (nucleophilic or electrophilic attack) nucleophile is required for its hydrolysis • Metal ion catalysis: Involvement of metal ion in catalysis. A metal ion is an electrophile and (i) may stabilize a negative • Catalytic strategy is covalent modification and charge on an intermediate; (ii) by attracting electrons from acid-base catalysis water, renders water more acidic (prone to loose a proton); (iii) • Contains catalytic triad of Ser, His and Asp. Ser is may bind to substrate and reduce activation energy a nucleophile and participates in covalent • Catalysis by approximation: In reactions requiring more than modification, His is a proton acceptor (base), Asp one substrate, the enzyme facilitates their interaction by serving stabilizes His (and active site) by electrostatic as an adapter that increases proximity of the substrates to each interactions other Reaction Mechanism Step-wise reaction • Hydrolysis by chymotrypsin is a 2-step process • Enzyme active site is stabilized by ionic interactions • Step 1: serine reacts with substrate to form covalent between Asp and His and H-bond between His and Ser. ES complex • In the presence of a substrate, His accepts a proton from • Step 2: release of products from ES complex and Ser, Ser makes a nucleophilic attack on the peptide’s regeneration of enzyme carbonyl C converting its geometry to tetrahedral.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS Et Al
    US 2016.0346364A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS et al. (43) Pub. Date: Dec. 1, 2016 (54) MEDICAMENT AND METHOD FOR (52) U.S. Cl. TREATING INNATE IMMUNE RESPONSE CPC ........... A61K 38/488 (2013.01); A61K 38/482 DISEASES (2013.01); C12Y 304/23019 (2013.01); C12Y 304/21026 (2013.01); C12Y 304/23018 (71) Applicant: DSM IPASSETS B.V., Heerlen (NL) (2013.01); A61K 9/0053 (2013.01); C12N 9/62 (2013.01); A23L 29/06 (2016.08); A2ID 8/042 (72) Inventors: Maaike Johanna BRUINS, Kaiseraugst (2013.01); A23L 5/25 (2016.08); A23V (CH); Luppo EDENS, Kaiseraugst 2002/00 (2013.01) (CH); Lenneke NAN, Kaiseraugst (CH) (57) ABSTRACT (21) Appl. No.: 15/101,630 This invention relates to a medicament or a dietary Supple (22) PCT Filed: Dec. 11, 2014 ment comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, (86). PCT No.: PCT/EP2014/077355 and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response S 371 (c)(1), in humans, and/or allowing to delay the onset of said (2) Date: Jun. 3, 2016 diseases. The present invention relates to the discovery that (30) Foreign Application Priority Data the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are Dec. 11, 2013 (EP) .................................. 13196580.8 present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, Publication Classification the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a (51) Int.
    [Show full text]
  • NS3 Protease from Flavivirus As a Target for Designing Antiviral Inhibitors Against Dengue Virus
    Genetics and Molecular Biology, 33, 2, 214-219 (2010) Copyright © 2010, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article NS3 protease from flavivirus as a target for designing antiviral inhibitors against dengue virus Satheesh Natarajan Department of Biochemistry, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malayasia. Abstract The development of novel therapeutic agents is essential for combating the increasing number of cases of dengue fever in endemic countries and among a large number of travelers from non-endemic countries. The dengue virus has three structural proteins and seven non-structural (NS) proteins. NS3 is a multifunctional protein with an N-terminal protease domain (NS3pro) that is responsible for proteolytic processing of the viral polyprotein, and a C-terminal region that contains an RNA triphosphatase, RNA helicase and RNA-stimulated NTPase domain that are essential for RNA replication. The serine protease domain of NS3 plays a central role in the replicative cycle of den- gue virus. This review discusses the recent structural and biological studies on the NS2B-NS3 protease-helicase and considers the prospects for the development of small molecules as antiviral drugs to target this fascinating, multifunctional protein. Key words: antiviral inhibitor, drug discovery, multifunctional protein, NS3, protease. Received: March 4, 2009; Accepted: November 1, 2009. Introduction seven non-structural proteins involved in viral replication The genus Flavivirus in the family Flaviviridae con- and maturation (Henchal and Putnak, 1990; Kautner et al., tains a large number of viral pathogens that cause severe 1996). The virus-encoded protease complex NS2B-NS3 is morbidity and mortality in humans and animals (Bancroft, responsible for cleaving the NS2A/NS2B, NS2B/NS3, 1996).
    [Show full text]
  • Serine Protease (Chymotrypsin) from Nocardiopsis Prasina Expressed in Bacillus Licheniformis
    SERINE PROTEASE (CHYMOTRYPSIN) FROM NOCARDIOPSIS PRASINA EXPRESSED IN BACILLUS LICHENIFORMIS Chemical and Technical Assessment Prepared by Jannavi R. Srinivasan, Ph.D., Reviewed by Dr. Inge Meyland, Ph. D. 1. Summary This Chemical and Technical Assessment (CTA) summarizes data and information on the serine protease with chymotrypsin specificity from Nocardiopsis prasina expressed in Bacillus Licheniformis enzyme preparation submitted to the Joint FAO/WHO Expert Committee on Food Additives (JECFA) by Novozymes A/S in a dossier dated November 25, 2011 (Novozymes, 2011)a. In this CTA, the expression ‘serine protease (chymotrypsin)’ is used when referring to the serine protease with chymotrypsin specificity enzyme and its amino acid sequence, whereas the expression ‘serine protease (chymotrypsin) enzyme preparation’ is used when referring to the enzyme preparation. This document also discusses published information relevant to serine protease (chymotrypsin), the B. licheniformis production organism, and the N. prasina organism that is the source for the serine protease (chymotrypsin) gene. Serine protease (chymotrypsin) catalyses the hydrolysis of peptide bonds in a protein, preferably at the carboxyl end of Tyr (Tyr-X), Phe (Phe-X), Trp (Trp-X), when X is not proline. It also catalyses the hydrolysis of peptide bonds at the carboxyl end of other amino acids, primarily Met and Leu, albeit at a slower rate. It is intended for use in the production of hydrolysed animal and vegetable proteins including casein, whey, soy isolate, soy concentrate, wheat gluten and corn gluten. These hydrolysed proteins will be used for various applications as ingredients in food, protein-fortified food, and beverages. The serine protease (chymotrypsin) enzyme preparation is expected to be inactivated during food processing.
    [Show full text]
  • Trypsin-Like Proteases and Their Role in Muco-Obstructive Lung Diseases
    International Journal of Molecular Sciences Review Trypsin-Like Proteases and Their Role in Muco-Obstructive Lung Diseases Emma L. Carroll 1,†, Mariarca Bailo 2,†, James A. Reihill 1 , Anne Crilly 2 , John C. Lockhart 2, Gary J. Litherland 2, Fionnuala T. Lundy 3 , Lorcan P. McGarvey 3, Mark A. Hollywood 4 and S. Lorraine Martin 1,* 1 School of Pharmacy, Queen’s University, Belfast BT9 7BL, UK; [email protected] (E.L.C.); [email protected] (J.A.R.) 2 Institute for Biomedical and Environmental Health Research, School of Health and Life Sciences, University of the West of Scotland, Paisley PA1 2BE, UK; [email protected] (M.B.); [email protected] (A.C.); [email protected] (J.C.L.); [email protected] (G.J.L.) 3 Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast BT9 7BL, UK; [email protected] (F.T.L.); [email protected] (L.P.M.) 4 Smooth Muscle Research Centre, Dundalk Institute of Technology, A91 HRK2 Dundalk, Ireland; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Trypsin-like proteases (TLPs) belong to a family of serine enzymes with primary substrate specificities for the basic residues, lysine and arginine, in the P1 position. Whilst initially perceived as soluble enzymes that are extracellularly secreted, a number of novel TLPs that are anchored in the cell membrane have since been discovered. Muco-obstructive lung diseases (MucOLDs) are Citation: Carroll, E.L.; Bailo, M.; characterised by the accumulation of hyper-concentrated mucus in the small airways, leading to Reihill, J.A.; Crilly, A.; Lockhart, J.C.; Litherland, G.J.; Lundy, F.T.; persistent inflammation, infection and dysregulated protease activity.
    [Show full text]
  • Inhibition of Human Matriptase by Eglin C Variants
    FEBS Letters 580 (2006) 2227–2232 Inhibition of human matriptase by eglin c variants Antoine De´silets, Jean-Michel Longpre´, Marie-E` ve Beaulieu, Richard Leduc* Department of Pharmacology, Faculty of Medicine and Health Sciences, Universite´ de Sherbrooke, Sherbrooke, Que., Canada J1H 5N4 Received 2 February 2006; revised 2 March 2006; accepted 9 March 2006 Available online 20 March 2006 Edited by Michael R. Bubb inhibitor eglin c [14,15]. Further studies based on the three- Abstract Based on the enzyme specificity of matriptase, a type II transmembrane serine protease (TTSP) overexpressed in epi- dimensional structure of eglin c have found that optimization thelial tumors, we screened a cDNA library expressing variants of interaction between enzyme and inhibitor could be ad- of the protease inhibitor eglin c in order to identify potent dressed by screening eglin c cDNA libraries containing ran- 0 matriptase inhibitors. The most potent of these, R1K4-eglin, domly substituted residues within projected adventitious which had the wild-type Pro45 (P1 position) and Tyr49 (P40 posi- contact sites outside the reactive site [16]. The similarity in tion) residues replaced with Arg and Lys, respectively, led to the specificity between matriptase and furin, which preferentially production of a selective, high affinity (Ki of 4 nM) and proteo- recognizes the R–X–X–R (P4 to P1 position) sequence [17], lytically stable inhibitor of matriptase. Screening for eglin c vari- led us to the hypothesis that matriptase and other members ants could yield specific, potent and stable inhibitors to of the TTSP family could be targets of genetically engineered matriptase and to other members of the TTSP family.
    [Show full text]
  • Schneider-Dissertation-2019
    Biosynthetic Investigation, Synthesis, and Bioactivity Evaluation of Putative Peptide Aldehyde Natural Products From the Human Gut Microbiota The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Schneider, Benjamin Aaron. 2019. Biosynthetic Investigation, Synthesis, and Bioactivity Evaluation of Putative Peptide Aldehyde Natural Products From the Human Gut Microbiota. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:42029686 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use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
    [Show full text]
  • Chymotrypsin C (Caldecrin) Promotes Degradation of Human Cationic Trypsin: Identity with Rinderknecht’S Enzyme Y
    Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: Identity with Rinderknecht’s enzyme Y Richa´ rd Szmola and Miklo´ s Sahin-To´ th* Department of Molecular and Cell Biology, Goldman School of Dental Medicine, Boston University, Boston, MA 02118 Communicated by Phillips W. Robbins, Boston Medical Center, Boston, MA, May 2, 2007 (received for review March 19, 2007) Digestive trypsins undergo proteolytic breakdown during their further tryptic sites (10). Autolysis was also proposed to play an transit in the human alimentary tract, which has been assumed to essential role in physiological trypsin degradation in the lower occur through trypsin-mediated cleavages, termed autolysis. Au- intestines. A number of studies in humans have demonstrated tolysis was also postulated to play a protective role against that trypsin becomes inactivated during its intestinal transit, and pancreatitis by eliminating prematurely activated intrapancreatic in the terminal ileum only Ϸ20% of the duodenal trypsin activity trypsin. However, autolysis of human cationic trypsin is very slow is detectable (12–14). On the basis of in vitro experiments, a in vitro, which is inconsistent with the documented intestinal theory was put forth that digestive enzymes are generally resis- trypsin degradation or a putative protective role. Here we report tant to each other and undergo degradation through autolysis that degradation of human cationic trypsin is triggered by chymo- only (10, 15). However, human cationic trypsin was shown to be trypsin C, which selectively cleaves the Leu81-Glu82 peptide bond highly resistant to autolysis, and appreciable autodegradation ؉ within the Ca2 binding loop. Further degradation and inactivation was observed only with extended incubation times in the com- of cationic trypsin is then achieved through tryptic cleavage of the plete absence of Ca2ϩ and salts (16–18).
    [Show full text]
  • Mixture of Trypsin, Chymotrypsin and Papain Reduces Formation of Metastases and Extends Survival Time of C57bl6 Mice with Syngeneic Melanoma B16
    Cancer Chemother Pharmacol #2001) 47 #Suppl): S16±S22 Ó Springer-Verlag 2001 ORIGINAL ARTICLE Martin Wald á Toma sÏ Oleja r á Veronika SÏ ebkova Marie Zadinova á Michal Boubelõ k á Pavla PoucÏ kova Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16 Abstract Purpose: The aim of the present study was to decreased expression of CD44 and CD54 molecules in investigate the eect of a mixture of proteolytic enzymes tumors exposed to proteolytic enzymes in vivo. #comprising trypsin, chymotrypsin and papain) on the Conclusions: Our data suggest that serine and cysteine metastatic model of syngeneic melanoma B16. Methods: proteinases suppress B16 melanoma, and restrict its 140 C57Bl6 mice were divided into two control and two metastatic dissemination in C57Bl6 mice. ``treated'' groups. Control groups received saline rectally, twice a day starting 24 h after intracutaneous Key words Trypsin á Papain á B16 melanoma á transplantation #C1) or from the time point of the Metastasis primary B16 melanoma extirpation #C2), respectively. ``Treated'' groups were rectally administered a mixture of 0.2 mg trypsin, 0.5 mg papain, and 0.2 mg chymo- Introduction trypsin twice daily starting 24 h after transplantation #E1) or after extirpation of the tumor #E2), respectively. Lack of requisite immune surveillance in tissue dier- Survival of mice and B16 melanoma generalization were entiation is an important mechanism that gives rise to a observed for a period of 100 days. Immunological clone of malignant cells, which eventuates in tumori- evaluation of B16 melanoma cells in the ascites was genesis.
    [Show full text]
  • TMPRSS2 and Furin Are Both Essential for Proteolytic Activation and Spread of SARS-Cov-2 in Human Airway Epithelial Cells and Pr
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.15.042085; this version posted April 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS- 2 CoV-2 in human airway epithelial cells and provide promising drug targets 3 4 5 Dorothea Bestle1#, Miriam Ruth Heindl1#, Hannah Limburg1#, Thuy Van Lam van2, Oliver 6 Pilgram2, Hong Moulton3, David A. Stein3, Kornelia Hardes2,4, Markus Eickmann1,5, Olga 7 Dolnik1,5, Cornelius Rohde1,5, Stephan Becker1,5, Hans-Dieter Klenk1, Wolfgang Garten1, 8 Torsten Steinmetzer2, and Eva Böttcher-Friebertshäuser1* 9 10 1) Institute of Virology, Philipps-University, Marburg, Germany 11 2) Institute of Pharmaceutical Chemistry, Philipps-University, Marburg, Germany 12 3) Department of Biomedical Sciences, Carlson College of Veterinary Medicine, Oregon 13 State University, Corvallis, USA 14 4) Fraunhofer Institute for Molecular Biology and Applied Ecology, Gießen, Germany 15 5) German Center for Infection Research (DZIF), Marburg-Gießen-Langen Site, Emerging 16 Infections Unit, Philipps-University, Marburg, Germany 17 18 #These authors contributed equally to this work. 19 20 *Corresponding author: Eva Böttcher-Friebertshäuser 21 Institute of Virology, Philipps-University Marburg 22 Hans-Meerwein-Straße 2, 35043 Marburg, Germany 23 Tel: 0049-6421-2866019 24 E-mail: [email protected] 25 26 Short title: TMPRSS2 and furin activate SARS-CoV-2 spike protein 27 28 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.15.042085; this version posted April 15, 2020.
    [Show full text]
  • Proteolytic Cleavage—Mechanisms, Function
    Review Cite This: Chem. Rev. 2018, 118, 1137−1168 pubs.acs.org/CR Proteolytic CleavageMechanisms, Function, and “Omic” Approaches for a Near-Ubiquitous Posttranslational Modification Theo Klein,†,⊥ Ulrich Eckhard,†,§ Antoine Dufour,†,¶ Nestor Solis,† and Christopher M. Overall*,†,‡ † ‡ Life Sciences Institute, Department of Oral Biological and Medical Sciences, and Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada ABSTRACT: Proteases enzymatically hydrolyze peptide bonds in substrate proteins, resulting in a widespread, irreversible posttranslational modification of the protein’s structure and biological function. Often regarded as a mere degradative mechanism in destruction of proteins or turnover in maintaining physiological homeostasis, recent research in the field of degradomics has led to the recognition of two main yet unexpected concepts. First, that targeted, limited proteolytic cleavage events by a wide repertoire of proteases are pivotal regulators of most, if not all, physiological and pathological processes. Second, an unexpected in vivo abundance of stable cleaved proteins revealed pervasive, functionally relevant protein processing in normal and diseased tissuefrom 40 to 70% of proteins also occur in vivo as distinct stable proteoforms with undocumented N- or C- termini, meaning these proteoforms are stable functional cleavage products, most with unknown functional implications. In this Review, we discuss the structural biology aspects and mechanisms
    [Show full text]
  • Intrinsic Evolutionary Constraints on Protease Structure, Enzyme
    Intrinsic evolutionary constraints on protease PNAS PLUS structure, enzyme acylation, and the identity of the catalytic triad Andrew R. Buller and Craig A. Townsend1 Departments of Biophysics and Chemistry, The Johns Hopkins University, Baltimore MD 21218 Edited by David Baker, University of Washington, Seattle, WA, and approved January 11, 2013 (received for review December 6, 2012) The study of proteolysis lies at the heart of our understanding of enzyme evolution remain unanswered. Because evolution oper- biocatalysis, enzyme evolution, and drug development. To un- ates through random forces, rationalizing why a particular out- derstand the degree of natural variation in protease active sites, come occurs is a difficult challenge. For example, the hydroxyl we systematically evaluated simple active site features from all nucleophile of a Ser protease was swapped for the thiol of Cys at serine, cysteine and threonine proteases of independent lineage. least twice in evolutionary history (9). However, there is not This convergent evolutionary analysis revealed several interre- a single example of Thr naturally substituting for Ser in the lated and previously unrecognized relationships. The reactive protease catalytic triad, despite its greater chemical similarity rotamer of the nucleophile determines which neighboring amide (9). Instead, the Thr proteases generate their N-terminal nu- can be used in the local oxyanion hole. Each rotamer–oxyanion cleophile through a posttranslational modification: cis-autopro- hole combination limits the location of the moiety facilitating pro- teolysis (10, 11). These facts constitute clear evidence that there ton transfer and, combined together, fixes the stereochemistry of is a strong selective pressure against Thr in the catalytic triad that catalysis.
    [Show full text]